Eli Lilly makes surprising retreat from major market
View original at finance.yahoo.comEli Lilly makes surprising retreat from major market Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The German drug pricing reform has the potential to significantly undermine predictability for pharmaceutical business operations
60% confidenceGermany will fall to last place among European markets when it comes to supporting the pharmaceutical industry if the proposed drug pricing reforms pass
60% confidenceCapital freed from the Germany investment reduction will be redirected toward Pennsylvania or a new U.S. manufacturing site
60% confidenceGerman state insurance fund deficits are forecast to balloon from 15.3 billion euros in 2027 to 40.4 billion euros in 2030 without reform
60% confidenceThe Alzey plant is still expected to open in 2027 but at reduced capacity with roughly 500 jobs instead of the planned 1,000
60% confidence
Data points we hold from this source
| Eli Lilly and Company · backlog | 2.3 billion_euros |